Page last updated: 2024-09-05

sb 203580 and glpg0634

sb 203580 has been researched along with glpg0634 in 1 studies

Compound Research Comparison

Studies
(sb 203580)
Trials
(sb 203580)
Recent Studies (post-2010)
(sb 203580)
Studies
(glpg0634)
Trials
(glpg0634)
Recent Studies (post-2010) (glpg0634)
3,48941,13713437133

Protein Interaction Comparison

ProteinTaxonomysb 203580 (IC50)glpg0634 (IC50)
Tyrosine-protein kinase JAK2Homo sapiens (human)1.9312
Macrophage colony-stimulating factor 1 receptorHomo sapiens (human)0.4889
Tyrosine-protein kinase JAK1Homo sapiens (human)0.8199
Non-receptor tyrosine-protein kinase TYK2Homo sapiens (human)0.9225
Vascular endothelial growth factor receptor 3Homo sapiens (human)0.274
Receptor-type tyrosine-protein kinase FLT3Homo sapiens (human)0.338
Tyrosine-protein kinase JAK3Homo sapiens (human)1.0867
Jak1 proteinRattus norvegicus (Norway rat)0.029

Research

Studies (1)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's0 (0.00)24.3611
2020's1 (100.00)2.80

Authors

AuthorsStudies
Bharate, SB; Raghuvanshi, R1

Other Studies

1 other study(ies) available for sb 203580 and glpg0634

ArticleYear
Recent Developments in the Use of Kinase Inhibitors for Management of Viral Infections.
    Journal of medicinal chemistry, 2022, 01-27, Volume: 65, Issue:2

    Topics: Antiviral Agents; COVID-19; COVID-19 Drug Treatment; Drug Approval; Drug Repositioning; High-Throughput Screening Assays; Humans; Protein Kinase Inhibitors; SARS-CoV-2; United States; United States Food and Drug Administration; Virus Diseases

2022